Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06281678 · ClinicalTrials.gov registry record · Phase 2
A Study of IBI363 in Subjects with Advanced Solid Malignancies
A Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Innovent Biologics (Suzhou) Co..
- Recruiting
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
- 9
- Study locations
NCT06281678 is a Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer that is actively recruiting participants, run by Innovent Biologics (Suzhou) Co.. The registered enrollment target is 178 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The trial reports 9 study locations across 6 states.
The verdict
NCT06281678, a Phase 2 study of Non-Small Cell Lung Cancer and Colorectal Cancer, is actively recruiting participants, sponsored by Innovent Biologics (Suzhou) Co..
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Conditions Studied
Interventions
- DRUG IBI363
Study Locations (9)
Florida
- Ocala Oncology Center - Ocala
- BRCR Medical Center - Plantation
Michigan
- Michigan Hematology & Oncology Consultants - MedOnc Dearborn - Dearborn
- Michigan Hematology & Oncology Consultants - MedOnc Troy - Troy
Texas
- MD Anderson Cancer Center-University of Texas - Houston
- Oncology Consultants P.A. - Houston
California
- University of California, San Francisco (UCSF) - San Francisco
Kansas
- University of Kansas Medical Center (KUMC) - Fairway
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06281678
The ClinicalTrials.gov registry entry for NCT06281678 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Innovent Biologics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which IBI363 is the first listed.
NCT06281678 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Florida, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT06281678 about?
NCT06281678 is a clinical study titled "A Study of IBI363 in Subjects with Advanced Solid Malignancies". This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
What is the current status of trial NCT06281678?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2024-04-08. Estimated completion is 2026-12-31.
What conditions does trial NCT06281678 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Melanoma, Renal Cell Cancer.
What interventions are being tested in trial NCT06281678?
The interventions under investigation include: IBI363 (DRUG).
Who is sponsoring clinical trial NCT06281678?
This trial is sponsored by Innovent Biologics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06281678 being conducted?
This trial has 9 study locations across California, Florida, Kansas, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.